Literature DB >> 32038946

Patients over 70 years of age with moderate ischemic mitral regurgitation undergoing surgical revascularization plus mitral valve repair: insights from a single-center study of propensity-matched data.

Qiang Ji1, Xiao-Min Qi2, Jin-Qiang Shen1, Yu-Lin Wang1, Ye Yang1, Wen-Jun Ding1, Li-Min Xia1,3, Chun-Sheng Wang2.   

Abstract

BACKGROUND: Elderly patients, compared with the young, have a higher burden of surgical risk factors with reduced functional capacity and increased comorbidities conditions, and may have worse clinical outcomes. So far, few reports have focused on clinical outcomes of patients over 70 years of age with moderate chronic ischemic mitral regurgitation (IMR) undergoing mitral valve repair at the time of coronary artery bypass grafting (CABG). This single-center study of propensity-matched data attempts to answer a question: compared with patients with age of 70 or less, whether patients over 70 years of age with moderate IMR undergoing CABG plus mitral valve repair receive poor outcomes.
METHODS: All eligible patients were included in this study and were entered into either an elderly group (n=142) or a control group (n=182) according to patients' age. In-hospital outcomes (consisting of surgical mortality and major postoperative morbidity) and midterm clinical outcomes (including all-cause mortality and recurrent mitral regurgitation) were compared after propensity score matching (1:1).
RESULTS: Using propensity-score matching, 103 pairs of patients were successfully established in a 1:1 ratio. No significant differences between the two matched groups were found with regard to surgical mortality (5.8% vs. 3.9%, P=0.754) and major postoperative morbidity. A total of 184 patients (91 in the elderly group and 93 in the control group) received regular follow-up visit with the median duration of 38 months [interquartile range (IQR), 27-56 months]. There were not any significant differences between the two matched groups regarding overall survival and recurrent IMR-free survival (stratified log-rank P=0.185 and stratified log-rank P=0.453, respectively). The elderly group as compared to the control group did not affect midterm mortality via cox proportional hazard regression (propensity score adjusted hazard ratio, 1.143; 95% confidence interval, 0.761-1.943; P=0.285).
CONCLUSIONS: Patients over 70 years of age with moderate chronic IMR undergoing combined CABG and mitral valve repair may receive favorable in-hospital and midterm clinical outcomes. 2019 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Elderly patients; coronary artery bypass grafting (CABG); ischemic mitral regurgitation (IMR); mitral valve repair; moderate; propensity-score matching

Year:  2019        PMID: 32038946      PMCID: PMC6987517          DOI: 10.21037/cdt.2019.10.06

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  21 in total

1.  Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients.

Authors:  F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin
Journal:  Eur J Cardiothorac Surg       Date:  1999-06       Impact factor: 4.191

2.  Development and validation of a risk calculator predicting postoperative respiratory failure.

Authors:  Himani Gupta; Prateek K Gupta; Xiang Fang; Weldon J Miller; Samuel Cemaj; R Armour Forse; Lee E Morrow
Journal:  Chest       Date:  2011-07-14       Impact factor: 9.410

3.  Should the mitral valve be repaired for moderate ischemic mitral regurgitation at the time of revascularization surgery?

Authors:  Mohammad Y Salmasi; Amer Harky; Mohammed F Chowdhury; Ali Abdelnour; Anastasia Benjafield; Farah Suker; Stephanie Hubbard; Hunaid A Vohra
Journal:  J Card Surg       Date:  2018-06-10       Impact factor: 1.620

4.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas
Journal:  J Am Coll Cardiol       Date:  2014-03-03       Impact factor: 24.094

5.  Five-year real world outcomes of GeoForm ring implantation in patients with ischemic mitral regurgitation.

Authors:  Tomasz A Timek; Robert L Hooker; Robin Collingwood; Alan T Davis; Craig T Alguire; Charles L Willekes; Edward T Murphy; John C Heiser; Lawrence H Patzelt
Journal:  J Thorac Cardiovasc Surg       Date:  2014-02-21       Impact factor: 5.209

6.  Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment.

Authors:  Luc A Piérard; Blase A Carabello
Journal:  Eur Heart J       Date:  2010-12-01       Impact factor: 29.983

Review 7.  Contemporary Management of Ischemic Mitral Regurgitation: A Review.

Authors:  Yader Sandoval; Paul Sorajja; Kevin M Harris
Journal:  Am J Med       Date:  2018-02-28       Impact factor: 4.965

8.  Does prior percutaneous coronary intervention adversely affect early and mid-term survival after coronary artery surgery?

Authors:  Cheng-Hon Yap; Bryan P Yan; Enoch Akowuah; Diem T Dinh; Julian A Smith; Gilbert C Shardey; James Tatoulis; Peter D Skillington; Andrew Newcomb; Morteza Mohajeri; Adrian Pick; Siven Seevanayagam; Christopher M Reid
Journal:  JACC Cardiovasc Interv       Date:  2009-08       Impact factor: 11.195

9.  OPCABG for Moderate CIMR in Elderly Patients: a Superior Option?

Authors:  Amber Malhotra; Chandrasekaran Ananthanarayanan; Vivek Wadhawa; Sumbul Siddiqui; Pranav Sharma; Kartik Patel; Komal Shah; Pratik Shah
Journal:  Braz J Cardiovasc Surg       Date:  2018 Jan-Feb

10.  Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial.

Authors:  K M John Chan; Prakash P Punjabi; Marcus Flather; Riccardo Wage; Karen Symmonds; Isabelle Roussin; Shelley Rahman-Haley; Dudley J Pennell; Philip J Kilner; Gilles D Dreyfus; John R Pepper
Journal:  Circulation       Date:  2012-11-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.